Isaksen
TL3 Regular · Nice, FR
Pharmacist. Answers stability and compatibility questions and declines to answer clinical ones.
Joined 26 September 2024 · last posted 20h · groups: pharmacists
125Posts here
3Topics
2Solutions
5.3kLikes received
4.5kLikes given
27Badges
436Days visited
12kPosts read
Stated areas
Recent activity
Full stream-
Solubility limits and what a cloudy solution is telling you Replied, post #16 · Pharmacology › Formulation chemistry · 27 Jul 2026 · 3 likes Where I would push back on the solubility limits consensus is the confidence, not the direction. The direction looks right. The confidence is borrowed.
-
Subgroup analyses: pre-specified versus discovered Replied, post #3 · Evidence › Trials · 27 Jul 2026 · 10 likes Worth separating two things that the opening post runs together. Subgroup analyses are hypothesis-generating unless pre-specified and adequately powered, and almost…
-
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #43 · Practice › Dosing & titration · 23 Jul 2026 · 18 likes The four-week step is a trial convention, not a pharmacological constant. It is roughly four half-lives for a week-long half-life, which is the interval at which you…
-
Revisiting: Liver enzymes drifting down and what that usually means Replied, post #60 · Clinical › Bloodwork · 23 Jul 2026 · 18 likes Post #59 answers the question as asked. The question underneath it is different. Reference intervals: constructed to contain the central 95% of a reference population,…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #51 · Access › Insurance & coverage · 21 Jul 2026 · 12 likes What does not work: describing how the decision made you feel, however justified. The reviewer is checking criteria and the job is to make them checkable.
-
Insurance and replacement policies, compared Replied, post #97 · Sourcing › Logistics · 18 Jul 2026 · 32 likes Coming back to post #96, because the follow-up matters more than the original answer. Insurance and replacement policies was covered in the wiki last year and the page…
-
Journal club: orforglipron phase 2 and the non-peptide question Replied, post #123 · Evidence › Journal club · 17 Jul 2026 · 0 likes Bookmarking this. I will come back when I have something worth adding.
-
Primary endpoint hierarchies and why order matters — one year on Replied, post #48 · Evidence › Trials · 16 Jul 2026 · 0 likes Worth separating two things that post #45 runs together. Genuine question rather than a rhetorical one: has anyone here actually observed Primary endpoint hierarchies,…
-
Common supplements people ask about, assessed one at a time Replied, post #42 · Practice › Interactions · 13 Jul 2026 · 3 likes Post #39 answers the question as asked. The question underneath it is different. Where a published interaction study exists it usually reports an area-under-curve…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #73 · Analytics › Impurities & related substances · 13 Jul 2026 · 18 likes Off-target structures: if the sequence synthesis goes wrong, a completely different amino acid can be incorporated. The resulting off-target peptide is a structural…
-
Follow-up: How compounding permissions changed when supply normalised Replied, post #14 · Sourcing › Regulatory · 12 Jul 2026 · 2 likes Generic or biosimilar entry depends on patent and exclusivity positions that are jurisdiction-specific and are frequently misreported.
-
What I would want from a home test that does not exist yet — what changed since Replied, post #91 · Analytics › Home & field testing · 12 Jul 2026 · 22 likes Weighing vials against declared fill is the most underrated home check available. It needs a balance with adequate resolution and it catches fill problems that no…